BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 70,907 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 70,907 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $361.90, for a total value of $25,661,243.30. Following the completion of the transaction, the chief executive officer directly owned 54,892 shares in the company, valued at approximately $19,865,414.80. This represents a 56.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Wednesday, August 12th, John Oyler sold 54,892 shares of BeOne Medicines stock. The shares were sold at an average price of $358.15, for a total value of $19,659,569.80.
• On Monday, August 10th, John Oyler sold 115,011 shares of BeOne Medicines stock. The shares were sold at an average price of $357.87, for a total value of $41,158,986.57.
• On Monday, July 20th, John Oyler sold 48,316 shares of BeOne Medicines stock. The stock was sold at an average price of $312.25, for a total value of $15,086,671.00.
• On Tuesday, July 21st, John Oyler sold 61,397 shares of BeOne Medicines stock. The stock was sold at an average price of $317.67, for a total value of $19,503,984.99.
• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The stock was sold at an average price of $298.34, for a total value of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total value of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The shares were sold at an average price of $305.95, for a total value of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total value of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total transaction of $501,360.76.

BeOne Medicines Price Performance

NASDAQ ONC opened at $359.05 on Thursday. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $253.95 and a 12 month high of $385.22. The stock has a market cap of $39.39 billion, a price-to-earnings ratio of 63.21 and a beta of 0.49. The company’s 50 day moving average is $301.40 and its two-hundred day moving average is $309.13.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.65. The business had revenue of $1.71 billion during the quarter, compared to analyst estimates of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. As a group, research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 7.3 earnings per share for the current year.

Key BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne Medicines and Revolution Medicines announced a partnership covering the clinical development and regional commercialization of oncology therapies. The agreement could expand BeOne’s cancer-treatment portfolio and future commercial opportunities. BeOne and Revolution Medicines partner for oncology therapies
• Positive Sentiment: Revolution Medicines shares rose after the market evaluated the BeOne-funded Phase 3 RAS(ON) collaboration, suggesting investors view the partnership as strategically meaningful for advancing targeted oncology treatments. The indirect benefit to ONC is tied to potential pipeline growth and future commercialization. Revolution Medicines rises after BeOne-funded Phase 3 RAS(ON) deal
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. The data does not indicate meaningful short-selling pressure, although the reported figures appear unusual and may have limited informational value.
• Negative Sentiment: CEO John Oyler sold 240,810 BeOne Medicines shares across transactions dated August 10–12 for approximately $86.5 million in total. The sales reduced his direct ownership substantially, which can weigh on investor sentiment; however, all three transactions were executed under a pre-arranged Rule 10b5-1 trading plan, reducing the signal that the sales reflect a new negative view of the company. SEC insider transaction filing

Wall Street Analyst Weigh In

ONC has been the subject of a number of analyst reports. TD Cowen increased their price target on BeOne Medicines from $424.00 to $454.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Wolfe Research restated an “outperform” rating and issued a $370.00 price objective on shares of BeOne Medicines in a research report on Monday. Citizens Jmp upped their price objective on BeOne Medicines from $396.00 to $405.00 and gave the stock a “market outperform” rating in a research note on Thursday, August 6th. Wells Fargo & Company began coverage on BeOne Medicines in a research note on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective for the company. Finally, Barclays lifted their target price on BeOne Medicines from $403.00 to $407.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, BeOne Medicines presently has a consensus rating of “Buy” and a consensus price target of $402.14.

Hedge Funds Weigh In On BeOne Medicines

Several institutional investors have recently bought and sold shares of ONC. BNP Paribas Financial Markets lifted its stake in BeOne Medicines by 100.6% in the 4th quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock worth $58,924,000 after purchasing an additional 97,244 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of BeOne Medicines during the first quarter valued at about $19,438,000. SEB Asset Management AB bought a new stake in shares of BeOne Medicines in the first quarter worth about $16,653,000. Capital International Sarl increased its holdings in shares of BeOne Medicines by 2.7% in the fourth quarter. Capital International Sarl now owns 152,515 shares of the company’s stock worth $46,336,000 after purchasing an additional 3,956 shares during the last quarter. Finally, Rokos Capital Management LLP purchased a new stake in shares of BeOne Medicines in the first quarter worth about $4,256,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.